Small Animal Specialist Hospital, 1/1 Richardson Place, North Ryde, NSW 2213 Australia (Todd, Nguyen, White, Langova, Tzannes); Small Animal Specialist Hospital, 2 Bounty Close, Tuggerah, NSW 2259 Australia (Thomas).
Can Vet J. 2021 Dec;62(12):1335-1340.
High-grade and metastatic canine mast cell tumors carry a guarded prognosis because of their unpredictable biologic behavior. An ideal chemotherapy regime is yet to be established. The aim of this study was to review the efficacy and toxicity of combination vinblastine and toceranib for high-grade and metastatic mast cell tumors. Twenty-eight dogs were categorized with either high-grade, lymph node metastasis or Stage IV disease. Demographics, disease, and treatment variables were compared between categories (Kruskal-Wallis test for continuous data and Fisher's Exact test for categorical data). Survival times and progression-free intervals (PFI) were calculated and compared between groups (log rank test). The PFI was 310 d [95% confidence interval (CI): 155 to 1425] and overall survival was 373 d (95% CI: 226 to 1219). There was no difference between disease categories for PFI ( = 0.9) or survival ( = 0.5). The protocol was well-tolerated with increased liver enzyme activity and gastrointestinal toxicity most frequently observed. Progression-free intervals and survival times were similar in dogs with high-grade, metastatic and Stage IV disease.
高等级和转移性犬肥大细胞瘤由于其不可预测的生物学行为，预后较差。目前还没有建立理想的化疗方案。本研究旨在回顾长春新碱和托塞拉尼联合治疗高等级和转移性肥大细胞瘤的疗效和毒性。28 只狗被归类为高等级、淋巴结转移或 IV 期疾病。对分类之间的人口统计学、疾病和治疗变量进行比较（连续数据的 Kruskal-Wallis 检验和分类数据的 Fisher 精确检验）。计算并比较各组之间的生存时间和无进展间隔（PFI）（对数秩检验）。PFI 为 310 d [95%置信区间（CI）：155 至 1425]，总生存期为 373 d（95%CI：226 至 1219）。PFI（=0.9）或生存（=0.5）在疾病分类之间无差异。该方案耐受性良好，最常观察到肝酶活性升高和胃肠道毒性。高等级、转移性和 IV 期疾病的犬无进展间隔和生存时间相似。
